Literature DB >> 28315269

Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection.

Linda Nguyen1,2, Brandon P Lucke-Wold3, Shona Mookerjee4, Nidhi Kaushal5, Rae R Matsumoto6,7.   

Abstract

Sigma-1 receptors are molecular chaperones that may act as pathological mediators and targets for novel therapeutic applications in neurodegenerative diseases. Accumulating evidence indicates that sigma-1 ligands can either directly or indirectly modulate multiple neurodegenerative processes, including excitotoxicity, calcium dysregulation, mitochondrial and endoplasmic reticulum dysfunction, inflammation, and astrogliosis. In addition, sigma-1 ligands may act as disease-modifying agents in the treatment for central nervous system (CNS) diseases by promoting the activity of neurotrophic factors and neural plasticity. Here, we summarize their neuroprotective and neurorestorative effects in different animal models of acute brain injury and chronic neurodegenerative diseases, and highlight their potential role in mitigating disease. Notably, current data suggest that sigma-1 receptor dysfunction worsens disease progression, whereas enhancement amplifies pre-existing functional mechanisms of neuroprotection and/or restoration to slow disease progression. Collectively, the data support a model of the sigma-1 receptor as an amplifier of intracellular signaling, and suggest future clinical applications of sigma-1 ligands as part of multi-therapy approaches to treat neurodegenerative diseases.

Entities:  

Keywords:  Alzheimer’s disease; Amyotrophic lateral sclerosis; Neurorestoration; Parkinson’s disease; Stroke

Mesh:

Substances:

Year:  2017        PMID: 28315269      PMCID: PMC5500918          DOI: 10.1007/978-3-319-50174-1_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  148 in total

Review 1.  Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection.

Authors:  Gregor Zündorf; Georg Reiser
Journal:  Antioxid Redox Signal       Date:  2010-10-06       Impact factor: 8.401

2.  Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease.

Authors:  Agnes A Luty; John B J Kwok; Carol Dobson-Stone; Clement T Loy; Kirsten G Coupland; Helena Karlström; Tomasz Sobow; Joanna Tchorzewska; Aleksandra Maruszak; Maria Barcikowska; Peter K Panegyres; Cezary Zekanowski; William S Brooks; Kelly L Williams; Ian P Blair; Karen A Mather; Perminder S Sachdev; Glenda M Halliday; Peter R Schofield
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

3.  Afobazole activation of σ-1 receptors modulates neuronal responses to amyloid-β25-35.

Authors:  Adam A Behensky; Ilya E Yasny; Alexander M Shuster; Sergei B Seredenin; Andrey V Petrov; Javier Cuevas
Journal:  J Pharmacol Exp Ther       Date:  2013-09-04       Impact factor: 4.030

4.  SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation.

Authors:  Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; James P O'Callaghan; Jason D Huber; Rae R Matsumoto
Journal:  Exp Neurol       Date:  2014-02-06       Impact factor: 5.330

5.  Membrane association facilitates degradation and cleavage of the cyclin-dependent kinase 5 activators p35 and p39.

Authors:  Seiji Minegishi; Akiko Asada; Shinya Miyauchi; Takahiro Fuchigami; Taro Saito; Shin-Ichi Hisanaga
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

6.  Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse.

Authors:  A Brown; D E McFarlin; C S Raine
Journal:  Lab Invest       Date:  1982-02       Impact factor: 5.662

Review 7.  The pharmacology of sigma-1 receptors.

Authors:  Tangui Maurice; Tsung-Ping Su
Journal:  Pharmacol Ther       Date:  2009-07-18       Impact factor: 12.310

8.  The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study.

Authors:  T A Mavlyutov; M L Epstein; K A Andersen; L Ziskind-Conhaim; A E Ruoho
Journal:  Neuroscience       Date:  2010-02-16       Impact factor: 3.590

9.  Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival.

Authors:  Tomohisa Mori; Teruo Hayashi; Eri Hayashi; Tsung-Ping Su
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

10.  Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor.

Authors:  T Omi; H Tanimukai; D Kanayama; Y Sakagami; S Tagami; M Okochi; T Morihara; M Sato; K Yanagida; A Kitasyoji; H Hara; K Imaizumi; T Maurice; N Chevallier; S Marchal; M Takeda; T Kudo
Journal:  Cell Death Dis       Date:  2014-07-17       Impact factor: 8.469

View more
  34 in total

1.  Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays.

Authors:  Hideaki Yano; Alessandro Bonifazi; Min Xu; Daryl A Guthrie; Stephanie N Schneck; Ara M Abramyan; Andrew D Fant; W Conrad Hong; Amy H Newman; Lei Shi
Journal:  Neuropharmacology       Date:  2018-01-31       Impact factor: 5.250

2.  Novel missense alleles of SIGMAR1 as tools to understand emerin-dependent gene silencing in response to cocaine.

Authors:  Adith S Arun; Chelsy R Eddings; Katherine L Wilson
Journal:  Exp Biol Med (Maywood)       Date:  2019-07-19

3.  The molecular chaperone sigma 1 receptor mediates rescue of retinal cone photoreceptor cells via modulation of NRF2.

Authors:  J Wang; J Zhao; X Cui; B A Mysona; S Navneet; A Saul; M Ahuja; N Lambert; I G Gazaryan; B Thomas; K E Bollinger; S B Smith
Journal:  Free Radic Biol Med       Date:  2019-02-10       Impact factor: 7.376

4.  Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics.

Authors:  Annadurai Thangaraj; Palsamy Periyasamy; Ming-Lei Guo; Ernest T Chivero; Shannon Callen; Shilpa Buch
Journal:  Autophagy       Date:  2019-04-28       Impact factor: 16.016

5.  Evaluation of [18F]F-TZ3108 for PET Imaging of Metabolic-Associated Fatty Liver Disease.

Authors:  Peiyi Huang; Zhijun Li; Tukang Peng; Jihua Yang; Lei Bi; Guolong Huang; Yifan Qiu; Min Yang; Peizhen Ye; Mingxing Huang; Hongjun Jin; Liao Sun
Journal:  Mol Imaging Biol       Date:  2022-06-15       Impact factor: 3.488

6.  Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer's Disease APP/PS1 Mouse Model.

Authors:  Héctor M Estévez-Silva; Germán Cuesto; Ninovska Romero; José Miguel Brito-Armas; Abraham Acevedo-Arozena; Ángel Acebes; Daniel J Marcellino
Journal:  Neurotherapeutics       Date:  2022-08-02       Impact factor: 6.088

7.  Neuroprotective Effects of σ2R/TMEM97 Receptor Modulators in the Neuronal Model of Huntington's Disease.

Authors:  Jing Jin; Nicolas Arbez; James J Sahn; Yan Lu; Kathryn T Linkens; Timothy R Hodges; Anthony Tang; Robyn Wiseman; Stephen F Martin; Christopher A Ross
Journal:  ACS Chem Neurosci       Date:  2022-09-15       Impact factor: 5.780

8.  Generation of Sigmar1 conditional knockout mouse using CRISPR-Cas9 gene targeting.

Authors:  Liang Huang; Haiyan Xiao; Xiaoling Xie; Fang Hu; Fulei Tang; Sylvia B Smith; Lin Gan
Journal:  Genesis       Date:  2022-05-28       Impact factor: 2.389

9.  Benzimidazolone-based selective σ2 receptor ligands: Synthesis and pharmacological evaluation.

Authors:  Sebastiano Intagliata; Walid F Alsharif; Christophe Mesangeau; Nicola Fazio; Michael Seminerio; Yan-Tong Xu; Rae R Matsumoto; Christopher R McCurdy
Journal:  Eur J Med Chem       Date:  2019-01-09       Impact factor: 6.514

10.  The role of sigma 1 receptor in organization of endoplasmic reticulum signaling microdomains.

Authors:  Vladimir Zhemkov; Jonathon A Ditlev; Wan-Ru Lee; Mikaela Wilson; Jen Liou; Michael K Rosen; Ilya Bezprozvanny
Journal:  Elife       Date:  2021-05-11       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.